Quince Therapeutics, Inc. · NASDAQ:QNCX
Quince Therapeutics — Investor Presentation (May 2026)
32 slides from Quince Therapeutics's investor presentation, May 18, 2026
Slide 1: Corporate Presentation May 18, 2026
Corporate Presentation May 18, 2026 A Subsidiary of Quince Therapeutics Exhibit 99.3
Slide 2: Disclaimers
Disclaimers The information in this Presentation has been prepared by Quince Therapeutics, Inc. (“Quince”) and Orphai Therapeutics, Inc. (“Orphai” and, together with Quince and each of Quince’s subsidiaries, the “company”) and contains information pertaining to the business and operations of the com
Slide 3: Quince Therapeutics / Orphai Transaction Highlights
Quince Therapeutics / Orphai Transaction Highlights Transaction Overview & Financing Governance & Leadership The acquisition of Orphai was structured as a stock-for-stock transaction whereby all of Orphai’s outstanding equity interests were exchanged for a combination of shares of Quince common stoc
Slide 4: Capitalization
Capitalization Calculated using the treasury stock method Excludes currently outstanding Orphai options that were assumed by Quince and warrants issued to Orphai warrant holders. Represents shares of Quince common stock issued to Orphai stockholders in connection with the merger, equal to 19.99% of
Slide 5: Investment Highlights
Investment Highlights Rare disease focused, clinical-staged biotechnology company developing a novel, once-daily, inhaled, disease modifying rapamycin formulation (LAM-001) across multiple Phase 2 programs: PH-ILD (~200K US/EU)1 –Current therapies are limited to vasodilation, not disease modifying2.
Slide 6: Quince Pipeline and Anticipated Milestones
Quince Pipeline and Anticipated Milestones 2026 2027 2028 Estimated US/EU Market Anticipated Data Readouts LAM-001 Pulmonary Hypertension-Interstitial Lung Disease (PH-ILD) ~200k 1Q-28 Bronchiolitis Obliterans Syndrome (BOS) ~30k 1Q-27 Sarcoidosis Associated PH (SAPH) ~60k 4Q-28 Phase 2 (IIT) Antici
Slide 7: Limitations of Oral Rapamycin
* Systemic bioavailability of 14 – 18% due to poor aqueous solubility, high molecular weight, extensive first‑pass metabolism, variable gastrointestinal conditions, food effects, and P‑glycoprotein-mediated efflux Rapamune (sirolimus) [prescribing information]. Pfizer Inc.; Revised 4/2017 Limitation
Slide 8: Solution: LAM-001 Designed for Improved Pulmonary Delivery of Rapamycin
Solution: LAM-001 Designed for Improved Pulmonary Delivery of Rapamycin Targeted Delivery: Direct lung delivery à higher local exposure versus oral or nebulized formulations Ideal Physical Chemical Properties for Lung Delivery: Enhanced lung exposure and potential improved efficacy in pulmonary dise
Slide 9: LAM-001: Inhaled Rapamycin Advantages over Oral
Phase 1/2 in LAM Patients LAM-001: Inhaled Rapamycin Advantages over Oral LAM-001 vs oral rapamycin: designed to deliver higher drug exposure in lungs where needed for clinical activity with lower systemic exposure where most toxicities arise Total dose delivered via inhalation = 20x lower (100 µg/d
Slide 10: LAM-001: Group Pulmonary Hypertension (PH-ILD)
LAM-001: Group 3 Pulmonary Hypertension (PH-ILD)
Slide 11: Pulmonary Hypertension (PH-ILD)
ILD = interstitial lung disease, * PH is categorized into 5 groups (Group1-5) based on disease etiology; Group 1: Pulmonary arterial hypertension, Group 2: PH due to left heart disease, Group 3: PH due to chronic lung disease (such as ILD or COPD) and/or hypoxia , Group 4: PH due to pulmonary artery
Slide 12: Rapamycin Targets PH Pathology
Rapamycin Targets PH Pathology PH Smooth Muscle cells (Hypoxia) Rapamycin FKBP12 Activated mTOR Inhibited mTOR ↑ mTOR signaling ↑ Proliferation ↓ mTOR signaling ↓ Proliferation Hypoxia Hypoxia +Rapamycin Krymskaya, et. al., FASEB (2011) Growth Factor R LAM-001 has been shown to reverse pulmonary art
Slide 13: Rapamycin Inhibits mTOR and Reverses PASMC Proliferation
Rapamycin Inhibits mTOR and Reverses Pulmonary Arterial Smooth Muscle Cell (PASMC) Proliferation1,2 1 Based on Goncharov, Circulation. 2014 129: 864. Contr = Control IPAH = Idiopathic Pulmonary Hypertension Rapamycin Reverses PASMC Proliferation2 2 Based on Houssaini, Am J Resp Cell Mol Bio 2013 PAS
Slide 14: Competitive Landscape PH-ILD Products and Product Candidates
Competitive Landscape PH-ILD Products and Product Candidates Company Once-daily dosing Vasodilation MOA Antiproliferative MOA Antifibrotic MOA Status LAM-001 Quince ✓ ✖ ✓ ✓ Ph 2 Tyvaso1 United Therapeutics ✖ ✓ ✖ ✖ Launched Yutrepia Liquidia ✖ ✓ ✖ ✖ Launched TPIP Insmed ✓ ✓ ✖ ✖ Ph 3 L606 Liquidia ✖ ✓
Slide 15: Phase 2a Trial of LAM-001 in Group 1 PAH and 3 PH
1iCPET is a diagnostic procedure in which patients undergo pulmonary and radial artery catheterization in conjunction with a bicycle exercise test to directly measure cardiac and pulmonary function during exercise. Bradley A. Maron, Barbara A. Cockrill, Aaron B. Waxman, David M. Systrom “Invasive Ca
Slide 16: Phase 2a Baseline Characteristics
Phase 2a Baseline Characteristics PAH PH-ILD Completers All Enrolled N per group 5 5 6 10 Female 4 2 2 6 Male 1 3 4 4 Age (median yr) 63 65 64 65 ILD IPF1 1 0 1 NSIP1 2 2 2 SSc- ILD1 1 1 1 PS1(Grp 5) 1 1 1 Background PH Meds Ambrisentan 2 0 1 2 Macitentan 3 1 2 4 Riociguat 1 0 0 1 Selexipag 1 0 0 1
Slide 17: Phase 2a 24 Week Data Summary
Evaluable Population PH-ILD Subgroup Mean Mean N = 6 N = 4 Δ 6MWD (m) +81.3 +67.4 Δ VO2 Max (% Predicted) +5.4% +6.7% % Δ PVR (exercise) -25.5% -35.3% % Δ PVR (supine) -28.1% -33.9% % Δ NT-proBNP -29.0% -28.8% Δ FVC (% Predicted) +4.8% +1.8% Phase 2a 24 Week Data Summary Consistent, clinically relev
Slide 18: Phase 2a Functional Class Endpoint
Phase 2a Functional Class Endpoint Symptom-free when physically active or resting Class: I Class: II No symptoms at rest, but normal activities such as climbing stairs, grocery shopping or making the bed cause some discomfort and shortness of breath Class: III Resting may be symptom-free, but normal
Slide 19: Safety Summary through 24-Weeks
Safety Summary through 24-Weeks No dose interruptions due to AEs No discontinuations due to drug No drug related SAEs LAM-001 was well tolerated Drug Related AEs Grade 1 Productive Cough (n = 1) - Resolving Grade 2 Cough (n = 1) - Not Resolved Grade 1 Gingivitis (n = 1) - Resolving AEs = Adverse Eve
Slide 20: Phase 2a Efficacy and Safety Summary
Phase 2a Efficacy and Safety Summary LAM-001 well tolerated No dose interruptions due to AE No discontinuations due to drug No drug related SAE Drug related AEs N = 2 cough (Grade 1, 2 ) N = 1 gingivitis (Grade 1) PH-ILD patients +67m improvement observed in 6MWD compares favorably to existing thera
Slide 21: Phase 2b Trial of LAM-001 in PH-ILD
*Proposed study design Clinical Worsening defined as the occurrence of one of the following: 1) Death, 2) Unplanned Lung or heart-lung transplantation, 3) PH specific hospitalization (>24 hrs), 4) Worsened Functional class 5) ≥ 15% decline in 6MWD from baseline PVR = Pulmonary Vascular Resistance, N
Slide 22: LAM-001: Bronchiolitis Obliterans (BOS)
LAM-001: Bronchiolitis Obliterans (BOS)
Slide 23: LAM-001: Bronchiolitis Obliterans (BOS) Market
LAM-001: Bronchiolitis Obliterans (BOS) Market BOS = Bronchiolitis Obliterans Syndrome3 Leading cause of death post lung transplantation (LT)1 Orphan Drug Designation granted US and Europe No FDA approved drugs ~4,000 lung transplants performed annually in US2 Estimated Addressable Patient Populatio
Slide 24: BOS Major Unmet Need
BOS Major Unmet Need 94% Percent of lung transplant patients develop BOS within 10 years of lung transplantation2 2.5 years Median survival (or re-transplantation) post development of BOS post lung transplantation4 1ISHLT Factsheet: https://www.ishlt.org/docs/default-source/default-document-library/
Slide 25: FEV1 is Key Measure of BOS Progression and Survival
FEV1 is Key Measure of BOS Progression and Survival Progression to Advanced BOS is Measured by FEV1 Decline* *Baseline = best post-transplant FEV1 Meyer 2014: DOI: 10.1183/09031936.00107514 1% ↓ in FEV1 is associated with a 3.4% ↑ Mortality (p < 0.001) Kneidinger 2022 doi: 10.3389/fmed.2022.897581 F
Slide 26: Rapamycin Stabilizes Pulmonary Function in Patients with BOS
1Based on Hernandez, et. al. Transplantation Proceedings, 2005. DOI: 10.1016/j.transproceed.2005.09.191 Mean FEV1 Values Before and After Rapamycin Rapamycin Stabilizes Pulmonary Function in Patients with BOS1 Oral rapamycin administered to patients with progressive BOS post lung transplant who had
Slide 27: Phase 2 Trial of LAM-001 in BOS
Phase 2 Trial of LAM-001 in BOS Design 100 µg LAM-001 qd Week 48 Randomized 1:1, Double Blind, Placebo controlled, 25 mo open-label extension, Investigator-initiated trial Inclusion >18 yo; Newly diagnosed BOS (grade 1-2); ≥200mL drop in FEV1 (moderate progressive BOS), Double lung transplant Assess
Slide 28: IP, Financial, & Milestones
IP, Financial, & Milestones». -
Slide 29: Broad IP Strategy Supporting LAM-001 Exclusivity
Broad IP Strategy Supporting LAM-001 Exclusivity Particle size Additional pending Formulation Delivery Dosage Use of composition Defined dosing regimens Specific indications FDA Orange Book Affords Protection for 3 Types of Patents Composition Claims Method Claims Drug Substance (DS) Drug Product (D
Slide 30: Oversubscribed $115M Financing
Oversubscribed $115 M Financing Led by Well-Capitalized with Funding from Leading Healthcare Investors May 2026 Financing Including
Slide 31: Anticipated Milestones
Anticipated Milestones 1Q27 LAM-001 BOS Phase 2 Data 1Q28 LAM-001 PH-ILD Phase 2b Data 4Q28 LAM-001 SAPH Phase 2 Data May ‘26 LAM-001 PH Phase 2a Data (Oral Presentation at ATS) ü
Slide 32: Thank You
Thank You
Quince Therapeutics — Investor Presentation (May 2026) on 6ix